share_log

Eli Lilly and Co | 8-K: Eli Lilly Reports Second Quarter 2024 Financial Results

Eli Lilly and Co | 8-K: Eli Lilly Reports Second Quarter 2024 Financial Results

礼来 | 8-K：礼来公布2024年第二季度财务业绩
美股SEC公告 ·  08/08 07:09

Moomoo AI 已提取核心信息

Eli Lilly and Co (LLY) reported a significant increase in its financial results for the second quarter of 2024, with revenue surging 36% to $11.3 billion, driven by strong sales of Mounjaro, Zepbound, and Verzenio. The company's earnings per share (EPS) also saw a substantial rise, with reported EPS up 68% to $3.28 and non-GAAP EPS increasing 86% to $3.92. This performance led to an upward revision of the full-year revenue guidance by $3 billion and EPS guidance by $2.05 to $2.60. The quarter also marked progress in the company's pipeline, including the U.S. FDA approval of Kisunla for Alzheimer's disease and Jaypirca in Japan for mantle cell lymphoma. Additionally, the company submitted tirzepatide for obstructive sleep apnea and obesity in the U.S. and EU, and reported positive results from a Phase 3 trial for heart failure with preserved ejection fraction and obesity. Eli Lilly's financial outlook for 2024 has improved, with revenue guidance now ranging from $45.4 to $46.6 billion and EPS guidance between $15.10 to $15.60 on a reported basis, and $16.10 to $16.60 on a non-GAAP basis.
Eli Lilly and Co (LLY) reported a significant increase in its financial results for the second quarter of 2024, with revenue surging 36% to $11.3 billion, driven by strong sales of Mounjaro, Zepbound, and Verzenio. The company's earnings per share (EPS) also saw a substantial rise, with reported EPS up 68% to $3.28 and non-GAAP EPS increasing 86% to $3.92. This performance led to an upward revision of the full-year revenue guidance by $3 billion and EPS guidance by $2.05 to $2.60. The quarter also marked progress in the company's pipeline, including the U.S. FDA approval of Kisunla for Alzheimer's disease and Jaypirca in Japan for mantle cell lymphoma. Additionally, the company submitted tirzepatide for obstructive sleep apnea and obesity in the U.S. and EU, and reported positive results from a Phase 3 trial for heart failure with preserved ejection fraction and obesity. Eli Lilly's financial outlook for 2024 has improved, with revenue guidance now ranging from $45.4 to $46.6 billion and EPS guidance between $15.10 to $15.60 on a reported basis, and $16.10 to $16.60 on a non-GAAP basis.
礼来公司（LLY）于2024年第二季度财报中报告财务业绩显著增长，营业收入增长36％至113亿美元，主要由Mounjaro，Zepbound和Verzenio的强劲销售推动。公司每股收益（EPS）也有显著增长，报告EPS上升68％至3.28美元，非GAAP EPS增长86％至3.92美元。这一表现导致全年营收指引上调30亿美元，每股收益指引上调2.05至2.60美元。此季度还标志着公司管线进展，包括Kisunla获得美国FDA批准用于治疗阿尔茨海默病，Jaypirca在日本用于曼托细胞淋巴瘤。此外，公司还向美国和欧盟提交了tirzepatide用于治疗阻塞性睡眠呼吸暂停和肥胖症，并报告了对保留射血分数和肥胖症的心力衰竭进行的第3期试验的积极结果。礼来公司2024年的财务前景有所改善，报告基础上的营收指引现在区间为454亿至466亿美元，每股收益指引在15.10至15.60美元之间，非GAAP基础上在16.10至16.60美元之间。
礼来公司（LLY）于2024年第二季度财报中报告财务业绩显著增长，营业收入增长36％至113亿美元，主要由Mounjaro，Zepbound和Verzenio的强劲销售推动。公司每股收益（EPS）也有显著增长，报告EPS上升68％至3.28美元，非GAAP EPS增长86％至3.92美元。这一表现导致全年营收指引上调30亿美元，每股收益指引上调2.05至2.60美元。此季度还标志着公司管线进展，包括Kisunla获得美国FDA批准用于治疗阿尔茨海默病，Jaypirca在日本用于曼托细胞淋巴瘤。此外，公司还向美国和欧盟提交了tirzepatide用于治疗阻塞性睡眠呼吸暂停和肥胖症，并报告了对保留射血分数和肥胖症的心力衰竭进行的第3期试验的积极结果。礼来公司2024年的财务前景有所改善，报告基础上的营收指引现在区间为454亿至466亿美元，每股收益指引在15.10至15.60美元之间，非GAAP基础上在16.10至16.60美元之间。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间